Summary (tl;dr)

Major Pharmaceuticals has issued a nationwide Class II recall for specific lots of levothyroxine sodium tablets in July 2026 due to subpotency, meaning the medication may contain less active ingredient than stated, potentially leading to inadequate treatment for thyroid conditions.

Essential Background

Levothyroxine is a synthetic thyroid hormone widely prescribed to treat hypothyroidism, a condition where the thyroid gland does not produce enough thyroid hormone. It is also used to treat thyroid cancer and Hashimoto's disease, among other conditions. The medication is crucial for maintaining proper metabolism, energy levels, and overall health, and its effectiveness relies on consistent and accurate dosage.

The Full Story

In July 2026, Major Pharmaceuticals initiated a voluntary nationwide recall of selected levothyroxine sodium tablets after routine stability testing revealed potency concerns. The U.S. Food and Drug Administration (FDA) classified this as a Class II recall, indicating that using the affected product could cause temporary or medically reversible adverse health consequences, with a remote probability of serious harm. The recall, which began on July 13, 2026, impacts various strengths, including 25, 50, 75, 88, 112, 125, and 150 microgram tablets, which were packaged and distributed by Major Pharmaceuticals, with some further distribution by Cardinal Health. This follows earlier recalls of levothyroxine products in 2025 by Intas Pharmaceuticals and Accord Healthcare, and in April 2026 by Macleods Pharma USA, Inc., all primarily due to subpotency issues.

Why It Matters

The recall of subpotent levothyroxine is significant because patients taking affected tablets may receive less thyroid hormone than intended, which could lead to under-treatment of their hypothyroidism. This can cause symptoms such as fatigue, weight gain, increased sensitivity to cold, constipation, dry skin, and depression to persist or worsen. Particularly vulnerable groups include pregnant patients, infants, the elderly, and individuals with heart disease or thyroid cancer, who may require closer monitoring. Healthcare providers emphasize that patients should not abruptly stop taking their medication or adjust their dose without consulting their doctor or pharmacist.

Geographic Location

• Indianapolis, Marion County, Indiana, United States (Major Pharmaceuticals, packer and distributor of recalled levothyroxine sodium tablets)
• United States (Nationwide distribution of recalled products)
• Washington, D.C., District of Columbia, United States (U.S. Food and Drug Administration, announced recall)